Skip to main content
An official website of the United States government

anti-CD3/anti-BCMA bispecific antibody TQB2934

A T-cell engaging, human, bispecific, immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD3/anti-BCMA bispecific antibody TQB2934 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Synonym:anti-BCMA/anti-CD3 bispecific antibody TQB2934
anti-CD3 x BCMA double-specific antibody TQB2934
anti-CD3/anti-BCMA T-cell engaging bispecific antibody TQB2934
anti-CD3/BCMA bispecific antibody TQB2934
bispecific antibody TQB2934
Code name:TQB 2934
TQB-2934
TQB2934
Search NCI's Drug Dictionary